NZ538809A - Thiazolidinone cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof - Google Patents

Info

Publication number

NZ538809A

NZ538809A NZ538809A NZ53880903A NZ538809A NZ 538809 A NZ538809 A NZ 538809A NZ 538809 A NZ538809 A NZ 538809A NZ 53880903 A NZ53880903 A NZ 53880903A NZ 538809 A NZ538809 A NZ 538809A

Authority

NZ

New Zealand

Prior art keywords

group

cftr

thiazolidinone

phenyl

trifluoromethyl

Prior art date

2002-09-30

Links

• Espacenet
• Global Dossier
• Discuss

• 108010079245 Cystic Fibrosis Transmembrane Conductance Regulator Proteins 0.000 title claims abstract description 174
• 102000012605 Cystic Fibrosis Transmembrane Conductance Regulator Human genes 0.000 title claims description 172
• 239000012268 protein inhibitor Substances 0.000 title description 2
• 229940121649 protein inhibitor Drugs 0.000 title description 2
• 150000001875 compounds Chemical class 0.000 claims abstract description 171
• 239000000203 mixture Substances 0.000 claims abstract description 48
• 230000000968 intestinal effect Effects 0.000 claims abstract description 43
• 125000005843 halogen group Chemical group 0.000 claims abstract description 41
• 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 35
• 239000001257 hydrogen Substances 0.000 claims abstract description 31
• 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 31
• 230000002401 inhibitory effect Effects 0.000 claims abstract description 24
• 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims abstract description 24
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract description 23
• 238000011282 treatment Methods 0.000 claims abstract description 23
• 230000001404 mediated effect Effects 0.000 claims abstract description 21
• 150000003839 salts Chemical class 0.000 claims abstract description 21
• 125000003396 thiol group Chemical group [H]S* 0.000 claims abstract description 20
• 206010012735 Diarrhoea Diseases 0.000 claims abstract description 19
• 125000003545 alkoxy group Chemical group 0.000 claims abstract description 19
• 150000002431 hydrogen Chemical class 0.000 claims abstract description 17
• 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims abstract description 17
• 125000000751 azo group Chemical group [*]N=N[*] 0.000 claims abstract description 15
• 230000001965 increasing effect Effects 0.000 claims abstract description 15
• 230000037427 ion transport Effects 0.000 claims abstract description 15
• BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims abstract description 14
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 13
• 239000003814 drug Substances 0.000 claims abstract description 13
• KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims abstract description 12
• 210000002011 intestinal secretion Anatomy 0.000 claims abstract description 12
• 238000004519 manufacturing process Methods 0.000 claims abstract description 9
• 208000030761 polycystic kidney disease Diseases 0.000 claims abstract description 8
• 208000007466 Male Infertility Diseases 0.000 claims abstract description 7
• 208000027866 inflammatory disease Diseases 0.000 claims abstract description 6
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 59
• 125000000217 alkyl group Chemical group 0.000 claims description 49
• 238000000034 method Methods 0.000 claims description 48
• 241000282414 Homo sapiens Species 0.000 claims description 45
• 201000003883 Cystic fibrosis Diseases 0.000 claims description 43
• 230000000694 effects Effects 0.000 claims description 38
• 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 24
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 16
• 239000000546 pharmaceutical excipient Substances 0.000 claims description 14
• JIMHYXZZCWVCMI-ZSOIEALJSA-N 4-[(z)-[4-oxo-2-sulfanylidene-3-[3-(trifluoromethyl)phenyl]-1,3-thiazolidin-5-ylidene]methyl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1\C=C/1C(=O)N(C=2C=C(C=CC=2)C(F)(F)F)C(=S)S\1 JIMHYXZZCWVCMI-ZSOIEALJSA-N 0.000 claims description 12
• 239000003085 diluting agent Substances 0.000 claims description 10
• 241000124008 Mammalia Species 0.000 claims description 8
• 239000003937 drug carrier Substances 0.000 claims description 8
• 239000008194 pharmaceutical composition Substances 0.000 claims description 8
• 201000009881 secretory diarrhea Diseases 0.000 claims description 7
• 241000283984 Rodentia Species 0.000 claims description 5
• 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 claims description 5
• 125000001246 bromo group Chemical group Br* 0.000 claims description 4
• 241000271566 Aves Species 0.000 claims description 2
• 238000000099 in vitro assay Methods 0.000 claims description 2
• 102000004169 proteins and genes Human genes 0.000 claims description 2
• 108090000623 proteins and genes Proteins 0.000 claims description 2
• 230000037406 food intake Effects 0.000 claims 1
• 125000004209 (C1-C8) alkyl group Chemical group 0.000 abstract 1
• 102000008371 intracellularly ATP-gated chloride channel activity proteins Human genes 0.000 abstract 1
• -1 3,4-dihydroxyphenyl Chemical group 0.000 description 112
• 210000004027 cell Anatomy 0.000 description 71
• 239000003112 inhibitor Substances 0.000 description 66
• 239000012530 fluid Substances 0.000 description 64
• 230000005764 inhibitory process Effects 0.000 description 63
• 241000699670 Mus sp. Species 0.000 description 54
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 46
• 230000028327 secretion Effects 0.000 description 42
• 102000009016 Cholera Toxin Human genes 0.000 description 41
• 108010049048 Cholera Toxin Proteins 0.000 description 41
• 239000000243 solution Substances 0.000 description 35
• OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 34
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 33
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 29
• 201000010099 disease Diseases 0.000 description 29
• 241000700159 Rattus Species 0.000 description 26
• 238000009825 accumulation Methods 0.000 description 26
• 210000004379 membrane Anatomy 0.000 description 20
• 239000012528 membrane Substances 0.000 description 20
• 108091006146 Channels Proteins 0.000 description 19
• 210000000056 organ Anatomy 0.000 description 18
• 239000011780 sodium chloride Substances 0.000 description 18
• SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 17
• 238000010171 animal model Methods 0.000 description 17
• OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 17
• 208000035475 disorder Diseases 0.000 description 17
• 238000005259 measurement Methods 0.000 description 17
• 210000001519 tissue Anatomy 0.000 description 17
• 238000002474 experimental method Methods 0.000 description 16
• 238000001802 infusion Methods 0.000 description 16
• 210000000936 intestine Anatomy 0.000 description 16
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
• 238000003556 assay Methods 0.000 description 15
• 230000036515 potency Effects 0.000 description 15
• 238000012216 screening Methods 0.000 description 15
• 208000024891 symptom Diseases 0.000 description 15
• 241001465754 Metazoa Species 0.000 description 14
• 238000004458 analytical method Methods 0.000 description 14
• 125000003118 aryl group Chemical group 0.000 description 14
• 210000002966 serum Anatomy 0.000 description 14
• 125000001072 heteroaryl group Chemical group 0.000 description 13
• 125000001424 substituent group Chemical group 0.000 description 13
• 239000003053 toxin Substances 0.000 description 13
• 231100000765 toxin Toxicity 0.000 description 13
• 108700012359 toxins Proteins 0.000 description 13
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
• 239000000556 agonist Substances 0.000 description 12
• 238000006243 chemical reaction Methods 0.000 description 12
• 230000032258 transport Effects 0.000 description 12
• 125000000753 cycloalkyl group Chemical group 0.000 description 11
• 238000001990 intravenous administration Methods 0.000 description 11
• 238000012360 testing method Methods 0.000 description 11
• 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 10
• 241000699666 Mus <mouse, genus> Species 0.000 description 10
• 239000002253 acid Substances 0.000 description 10
• 150000002148 esters Chemical class 0.000 description 10
• 102000011279 Multidrug resistance protein 1 Human genes 0.000 description 9
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
• 238000010521 absorption reaction Methods 0.000 description 9
• 230000003247 decreasing effect Effects 0.000 description 9
• 238000009826 distribution Methods 0.000 description 9
• 231100000673 dose–response relationship Toxicity 0.000 description 9
• 125000000623 heterocyclic group Chemical group 0.000 description 9
• 239000007928 intraperitoneal injection Substances 0.000 description 9
• 210000004185 liver Anatomy 0.000 description 9
• 125000006239 protecting group Chemical group 0.000 description 9
• 230000000638 stimulation Effects 0.000 description 9
• 238000003786 synthesis reaction Methods 0.000 description 9
• 210000002700 urine Anatomy 0.000 description 9
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 8
• NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 8
• 210000000941 bile Anatomy 0.000 description 8
• 239000003795 chemical substances by application Substances 0.000 description 8
• 239000003623 enhancer Substances 0.000 description 8
• 239000008103 glucose Substances 0.000 description 8
• 239000007924 injection Substances 0.000 description 8
• 238000002347 injection Methods 0.000 description 8
• 238000007912 intraperitoneal administration Methods 0.000 description 8
• 125000000962 organic group Chemical group 0.000 description 8
• 230000035515 penetration Effects 0.000 description 8
• 230000000144 pharmacologic effect Effects 0.000 description 8
• 210000000813 small intestine Anatomy 0.000 description 8
• 239000002904 solvent Substances 0.000 description 8
• 239000000126 substance Substances 0.000 description 8
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 7
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 7
• QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 7
• 239000012190 activator Substances 0.000 description 7
• 125000003342 alkenyl group Chemical group 0.000 description 7
• 125000004414 alkyl thio group Chemical group 0.000 description 7
• 125000000304 alkynyl group Chemical group 0.000 description 7
• 230000015572 biosynthetic process Effects 0.000 description 7
• 239000008280 blood Substances 0.000 description 7
• 125000006575 electron-withdrawing group Chemical group 0.000 description 7
• 125000000524 functional group Chemical group 0.000 description 7
• 229960004580 glibenclamide Drugs 0.000 description 7
• ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 7
• 150000002430 hydrocarbons Chemical group 0.000 description 7
• 230000007246 mechanism Effects 0.000 description 7
• 239000002244 precipitate Substances 0.000 description 7
• 238000002360 preparation method Methods 0.000 description 7
• 239000000651 prodrug Substances 0.000 description 7
• 229940002612 prodrug Drugs 0.000 description 7
• 239000011541 reaction mixture Substances 0.000 description 7
• 229910052717 sulfur Inorganic materials 0.000 description 7
• 239000011593 sulfur Substances 0.000 description 7
• 229960004528 vincristine Drugs 0.000 description 7
• QGJOPFRUJISHPQ-UHFFFAOYSA-N Carbon disulfide Chemical compound S=C=S QGJOPFRUJISHPQ-UHFFFAOYSA-N 0.000 description 6
• 241000282412 Homo Species 0.000 description 6
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
• TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 6
• ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
• ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
• XSDQTOBWRPYKKA-UHFFFAOYSA-N amiloride Chemical compound NC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N XSDQTOBWRPYKKA-UHFFFAOYSA-N 0.000 description 6
• 229960002576 amiloride Drugs 0.000 description 6
• 125000003710 aryl alkyl group Chemical group 0.000 description 6
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 6
• 239000002585 base Substances 0.000 description 6
• 210000004369 blood Anatomy 0.000 description 6
• 230000037396 body weight Effects 0.000 description 6
• 210000000424 bronchial epithelial cell Anatomy 0.000 description 6
• 239000000872 buffer Substances 0.000 description 6
• KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
• 229940079593 drug Drugs 0.000 description 6
• 238000009472 formulation Methods 0.000 description 6
• 125000001188 haloalkyl group Chemical group 0.000 description 6
• 239000010410 layer Substances 0.000 description 6
• 210000004072 lung Anatomy 0.000 description 6
• 239000000463 material Substances 0.000 description 6
• 238000010172 mouse model Methods 0.000 description 6
• 230000035699 permeability Effects 0.000 description 6
• UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
• VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 5
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
• 238000006000 Knoevenagel condensation reaction Methods 0.000 description 5
• 125000001931 aliphatic group Chemical group 0.000 description 5
• 230000001142 anti-diarrhea Effects 0.000 description 5
• 125000004429 atom Chemical group 0.000 description 5
• 239000002775 capsule Substances 0.000 description 5
• 210000001072 colon Anatomy 0.000 description 5
• 125000004122 cyclic group Chemical group 0.000 description 5
• 230000002950 deficient Effects 0.000 description 5
• 235000014113 dietary fatty acids Nutrition 0.000 description 5
• 239000002552 dosage form Substances 0.000 description 5
• 239000000194 fatty acid Substances 0.000 description 5
• 229930195729 fatty acid Natural products 0.000 description 5
• 230000006870 function Effects 0.000 description 5
• 125000004435 hydrogen atom Chemical group [H]* 0.000 description 5
• 238000001727 in vivo Methods 0.000 description 5
• 150000002500 ions Chemical class 0.000 description 5
• 210000003734 kidney Anatomy 0.000 description 5
• 239000011159 matrix material Substances 0.000 description 5
• 239000001301 oxygen Substances 0.000 description 5
• 229910052760 oxygen Inorganic materials 0.000 description 5
• 230000037361 pathway Effects 0.000 description 5
• 239000003961 penetration enhancing agent Substances 0.000 description 5
• 210000002381 plasma Anatomy 0.000 description 5
• 229920001223 polyethylene glycol Polymers 0.000 description 5
• 239000000047 product Substances 0.000 description 5
• 230000002829 reductive effect Effects 0.000 description 5
• 208000023504 respiratory system disease Diseases 0.000 description 5
• 230000004044 response Effects 0.000 description 5
• 210000002027 skeletal muscle Anatomy 0.000 description 5
• 238000003756 stirring Methods 0.000 description 5
• 125000000547 substituted alkyl group Chemical group 0.000 description 5
• 239000000829 suppository Substances 0.000 description 5
• 239000003826 tablet Substances 0.000 description 5
• 210000001550 testis Anatomy 0.000 description 5
• 108091005957 yellow fluorescent proteins Proteins 0.000 description 5
• HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 4
• JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 4
• MRDJXDJVVCNDND-UHFFFAOYSA-N 2-sulfanylidene-3-[3-(trifluoromethyl)phenyl]-1,3-thiazolidin-4-one Chemical compound FC(F)(F)C1=CC=CC(N2C(SCC2=O)=S)=C1 MRDJXDJVVCNDND-UHFFFAOYSA-N 0.000 description 4
• ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 4
• GOUHYARYYWKXHS-UHFFFAOYSA-N 4-formylbenzoic acid Chemical compound OC(=O)C1=CC=C(C=O)C=C1 GOUHYARYYWKXHS-UHFFFAOYSA-N 0.000 description 4
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
• YUFCOOWNNHGGOD-UMMCILCDSA-N 8-bromo-3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1Br YUFCOOWNNHGGOD-UMMCILCDSA-N 0.000 description 4
• 241000282898 Sus scrofa Species 0.000 description 4
• 230000003187 abdominal effect Effects 0.000 description 4
• 229960000583 acetic acid Drugs 0.000 description 4
• 230000004913 activation Effects 0.000 description 4
• 239000002671 adjuvant Substances 0.000 description 4
• 125000002877 alkyl aryl group Chemical group 0.000 description 4
• 238000000376 autoradiography Methods 0.000 description 4
• 238000003287 bathing Methods 0.000 description 4
• 244000309464 bull Species 0.000 description 4
• DKVNPHBNOWQYFE-UHFFFAOYSA-N carbamodithioic acid Chemical compound NC(S)=S DKVNPHBNOWQYFE-UHFFFAOYSA-N 0.000 description 4
• 150000003857 carboxamides Chemical class 0.000 description 4
• 150000001732 carboxylic acid derivatives Chemical class 0.000 description 4
• 210000004534 cecum Anatomy 0.000 description 4
• 210000002808 connective tissue Anatomy 0.000 description 4
• 239000013078 crystal Substances 0.000 description 4
• 230000001419 dependent effect Effects 0.000 description 4
• 239000012990 dithiocarbamate Substances 0.000 description 4
• 230000008030 elimination Effects 0.000 description 4
• 238000003379 elimination reaction Methods 0.000 description 4
• 125000001153 fluoro group Chemical group F* 0.000 description 4
• 210000003405 ileum Anatomy 0.000 description 4
• CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 4
• 230000004941 influx Effects 0.000 description 4
• 230000003834 intracellular effect Effects 0.000 description 4
• 229910052757 nitrogen Inorganic materials 0.000 description 4
• 210000000496 pancreas Anatomy 0.000 description 4
• 235000019271 petrolatum Nutrition 0.000 description 4
• 239000000825 pharmaceutical preparation Substances 0.000 description 4
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
• YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
• 229920006395 saturated elastomer Polymers 0.000 description 4
• 210000003491 skin Anatomy 0.000 description 4
• 239000007787 solid Substances 0.000 description 4
• 230000001225 therapeutic effect Effects 0.000 description 4
• 238000002560 therapeutic procedure Methods 0.000 description 4
• 238000004809 thin layer chromatography Methods 0.000 description 4
• 231100000419 toxicity Toxicity 0.000 description 4
• 230000001988 toxicity Effects 0.000 description 4
• 210000003462 vein Anatomy 0.000 description 4
• OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 4
• OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 4
• BUNGCZLFHHXKBX-UHFFFAOYSA-N 8-methoxypsoralen Natural products C1=CC(=O)OC2=C1C=C1CCOC1=C2OC BUNGCZLFHHXKBX-UHFFFAOYSA-N 0.000 description 3
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
• JIMHYXZZCWVCMI-UHFFFAOYSA-N CFTRinh-172 Chemical compound C1=CC(C(=O)O)=CC=C1C=C1C(=O)N(C=2C=C(C=CC=2)C(F)(F)F)C(=S)S1 JIMHYXZZCWVCMI-UHFFFAOYSA-N 0.000 description 3
• 241000282465 Canis Species 0.000 description 3
• WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 3
• 108010078791 Carrier Proteins Proteins 0.000 description 3
• 206010008631 Cholera Diseases 0.000 description 3
• 241000283073 Equus caballus Species 0.000 description 3
• LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
• 241000282324 Felis Species 0.000 description 3
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
• 239000007995 HEPES buffer Substances 0.000 description 3
• 208000022559 Inflammatory bowel disease Diseases 0.000 description 3
• OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
• QXKHYNVANLEOEG-UHFFFAOYSA-N Methoxsalen Chemical compound C1=CC(=O)OC2=C1C=C1C=COC1=C2OC QXKHYNVANLEOEG-UHFFFAOYSA-N 0.000 description 3
• 229930182555 Penicillin Natural products 0.000 description 3
• JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
• 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
• 239000002202 Polyethylene glycol Substances 0.000 description 3
• 241000288906 Primates Species 0.000 description 3
• KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 3
• AOBORMOPSGHCAX-UHFFFAOYSA-N Tocophersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-UHFFFAOYSA-N 0.000 description 3
• 238000010751 Ullmann type reaction Methods 0.000 description 3
• 241000607626 Vibrio cholerae Species 0.000 description 3
• 230000003213 activating effect Effects 0.000 description 3
• 125000002252 acyl group Chemical group 0.000 description 3
• 239000000654 additive Substances 0.000 description 3
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
• 230000036760 body temperature Effects 0.000 description 3
• 239000007853 buffer solution Substances 0.000 description 3
• 239000006172 buffering agent Substances 0.000 description 3
• 230000000112 colonic effect Effects 0.000 description 3
• 210000004922 colonic epithelial cell Anatomy 0.000 description 3
• 238000011161 development Methods 0.000 description 3
• 150000002084 enol ethers Chemical class 0.000 description 3
• 150000004665 fatty acids Chemical class 0.000 description 3
• 239000012894 fetal calf serum Substances 0.000 description 3
• 230000002496 gastric effect Effects 0.000 description 3
• 230000002068 genetic effect Effects 0.000 description 3
• TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 3
• 229910052736 halogen Inorganic materials 0.000 description 3
• 150000002367 halogens Chemical class 0.000 description 3
• 230000036541 health Effects 0.000 description 3
• 238000010438 heat treatment Methods 0.000 description 3
• 125000004475 heteroaralkyl group Chemical group 0.000 description 3
• 125000005842 heteroatom Chemical group 0.000 description 3
• 230000001771 impaired effect Effects 0.000 description 3
• 230000000670 limiting effect Effects 0.000 description 3
• 239000007788 liquid Substances 0.000 description 3
• 229910001629 magnesium chloride Inorganic materials 0.000 description 3
• 230000028161 membrane depolarization Effects 0.000 description 3
• 229960004469 methoxsalen Drugs 0.000 description 3
• SQBBOVROCFXYBN-UHFFFAOYSA-N methoxypsoralen Natural products C1=C2OC(=O)C(OC)=CC2=CC2=C1OC=C2 SQBBOVROCFXYBN-UHFFFAOYSA-N 0.000 description 3
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
• 229910000402 monopotassium phosphate Inorganic materials 0.000 description 3
• 230000035772 mutation Effects 0.000 description 3
• VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
• 231100000252 nontoxic Toxicity 0.000 description 3
• 230000003000 nontoxic effect Effects 0.000 description 3
• 230000007310 pathophysiology Effects 0.000 description 3
• 229940049954 penicillin Drugs 0.000 description 3
• WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 3
• 230000008823 permeabilization Effects 0.000 description 3
• 230000002688 persistence Effects 0.000 description 3
• 238000007747 plating Methods 0.000 description 3
• 230000003389 potentiating effect Effects 0.000 description 3
• 238000000746 purification Methods 0.000 description 3
• 230000009467 reduction Effects 0.000 description 3
• 238000011160 research Methods 0.000 description 3
• 238000003345 scintillation counting Methods 0.000 description 3
• 239000012453 solvate Substances 0.000 description 3
• 229960005322 streptomycin Drugs 0.000 description 3
• 238000001356 surgical procedure Methods 0.000 description 3
• 239000003981 vehicle Substances 0.000 description 3
• JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 2
• KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 2
• XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 description 2
• SBASXUCJHJRPEV-UHFFFAOYSA-N 2-(2-methoxyethoxy)ethanol Chemical compound COCCOCCO SBASXUCJHJRPEV-UHFFFAOYSA-N 0.000 description 2
• SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 2
• LZCOBWKVDSSOBB-UHFFFAOYSA-N 2-pyridin-4-yl-4-benzo[h][1]benzopyranone Chemical compound O1C2=C3C=CC=CC3=CC=C2C(=O)C=C1C1=CC=NC=C1 LZCOBWKVDSSOBB-UHFFFAOYSA-N 0.000 description 2
• XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 2
• HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 2
• WBSMIPAMAXNXFS-UHFFFAOYSA-N 5-Nitro-2-(3-phenylpropylamino)benzoic acid Chemical compound OC(=O)C1=CC([N+]([O-])=O)=CC=C1NCCCC1=CC=CC=C1 WBSMIPAMAXNXFS-UHFFFAOYSA-N 0.000 description 2
• 208000030507 AIDS Diseases 0.000 description 2
• 229920001817 Agar Polymers 0.000 description 2
• APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 2
• 206010002091 Anaesthesia Diseases 0.000 description 2
• BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
• 241000283690 Bos taurus Species 0.000 description 2
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
• 241000193163 Clostridioides difficile Species 0.000 description 2
• 206010009900 Colitis ulcerative Diseases 0.000 description 2
• 229920002261 Corn starch Polymers 0.000 description 2
• 229920000858 Cyclodextrin Polymers 0.000 description 2
• RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
• IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
• 108010016626 Dipeptides Proteins 0.000 description 2
• AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
• 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
• LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 2
• 101710146739 Enterotoxin Proteins 0.000 description 2
• 241000588724 Escherichia coli Species 0.000 description 2
• 102100023374 Forkhead box protein M1 Human genes 0.000 description 2
• VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
• AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
• 101000907783 Homo sapiens Cystic fibrosis transmembrane conductance regulator Proteins 0.000 description 2
• 101000907578 Homo sapiens Forkhead box protein M1 Proteins 0.000 description 2
• 102000004310 Ion Channels Human genes 0.000 description 2
• 108090000862 Ion Channels Proteins 0.000 description 2
• 239000007836 KH2PO4 Substances 0.000 description 2
• YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 2
• 241000283953 Lagomorpha Species 0.000 description 2
• 208000019693 Lung disease Diseases 0.000 description 2
• AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
• FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
• 239000004264 Petrolatum Substances 0.000 description 2
• 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
• 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
• NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
• ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
• JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
• LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
• 241000700157 Rattus norvegicus Species 0.000 description 2
• 241000702670 Rotavirus Species 0.000 description 2
• 241000607142 Salmonella Species 0.000 description 2
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
• 229910021607 Silver chloride Inorganic materials 0.000 description 2
• QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
• 108050000353 Sulphonylurea receptors Proteins 0.000 description 2
• 102000009467 Sulphonylurea receptors Human genes 0.000 description 2
• GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
• 201000006704 Ulcerative Colitis Diseases 0.000 description 2
• XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
• 230000005856 abnormality Effects 0.000 description 2
• 230000002378 acidificating effect Effects 0.000 description 2
• 150000007513 acids Chemical class 0.000 description 2
• 230000001154 acute effect Effects 0.000 description 2
• 125000004423 acyloxy group Chemical group 0.000 description 2
• 239000000443 aerosol Substances 0.000 description 2
• 239000008272 agar Substances 0.000 description 2
• 125000002723 alicyclic group Chemical group 0.000 description 2
• 125000004448 alkyl carbonyl group Chemical group 0.000 description 2
• 125000005907 alkyl ester group Chemical group 0.000 description 2
• 125000003277 amino group Chemical group 0.000 description 2
• APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 2
• 229960003942 amphotericin b Drugs 0.000 description 2
• 230000037005 anaesthesia Effects 0.000 description 2
• KZNIFHPLKGYRTM-UHFFFAOYSA-N apigenin Chemical compound C1=CC(O)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C=C2O1 KZNIFHPLKGYRTM-UHFFFAOYSA-N 0.000 description 2
• 229940117893 apigenin Drugs 0.000 description 2
• XADJWCRESPGUTB-UHFFFAOYSA-N apigenin Natural products C1=CC(O)=CC=C1C1=CC(=O)C2=CC(O)=C(O)C=C2O1 XADJWCRESPGUTB-UHFFFAOYSA-N 0.000 description 2
• 235000008714 apigenin Nutrition 0.000 description 2
• 230000001580 bacterial effect Effects 0.000 description 2
• 230000008901 benefit Effects 0.000 description 2
• MYONAGGJKCJOBT-UHFFFAOYSA-N benzimidazol-2-one Chemical compound C1=CC=CC2=NC(=O)N=C21 MYONAGGJKCJOBT-UHFFFAOYSA-N 0.000 description 2
• 125000005605 benzo group Chemical group 0.000 description 2
• 239000011230 binding agent Substances 0.000 description 2
• 230000008499 blood brain barrier function Effects 0.000 description 2
• 210000001218 blood-brain barrier Anatomy 0.000 description 2
• 210000001124 body fluid Anatomy 0.000 description 2
• 210000004556 brain Anatomy 0.000 description 2
• AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
• 229910052799 carbon Inorganic materials 0.000 description 2
• 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
• 150000001733 carboxylic acid esters Chemical group 0.000 description 2
• 239000013553 cell monolayer Substances 0.000 description 2
• 239000001913 cellulose Substances 0.000 description 2
• 229920002678 cellulose Polymers 0.000 description 2
• 238000005119 centrifugation Methods 0.000 description 2
• 238000012512 characterization method Methods 0.000 description 2
• 238000007385 chemical modification Methods 0.000 description 2
• 125000001309 chloro group Chemical group Cl* 0.000 description 2
• 230000004087 circulation Effects 0.000 description 2
• 235000015165 citric acid Nutrition 0.000 description 2
• 238000003271 compound fluorescence assay Methods 0.000 description 2
• 238000009833 condensation Methods 0.000 description 2
• 230000005494 condensation Effects 0.000 description 2
• 238000013270 controlled release Methods 0.000 description 2
• 239000008120 corn starch Substances 0.000 description 2
• DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
• 125000004093 cyano group Chemical group *C#N 0.000 description 2
• 230000001086 cytosolic effect Effects 0.000 description 2
• 230000007547 defect Effects 0.000 description 2
• 230000007812 deficiency Effects 0.000 description 2
• 229960004042 diazoxide Drugs 0.000 description 2
• ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 2
• 229940043237 diethanolamine Drugs 0.000 description 2
• XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 2
• 125000004982 dihaloalkyl group Chemical group 0.000 description 2
• XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
• ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
• ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 2
• 235000019797 dipotassium phosphate Nutrition 0.000 description 2
• 229910000396 dipotassium phosphate Inorganic materials 0.000 description 2
• 238000002224 dissection Methods 0.000 description 2
• POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
• 239000003995 emulsifying agent Substances 0.000 description 2
• 230000001804 emulsifying effect Effects 0.000 description 2
• 210000001842 enterocyte Anatomy 0.000 description 2
• 230000000688 enterotoxigenic effect Effects 0.000 description 2
• 239000000147 enterotoxin Substances 0.000 description 2
• 231100000655 enterotoxin Toxicity 0.000 description 2
• 210000002919 epithelial cell Anatomy 0.000 description 2
• 125000004185 ester group Chemical group 0.000 description 2
• 230000032050 esterification Effects 0.000 description 2
• 238000005886 esterification reaction Methods 0.000 description 2
• 229940031098 ethanolamine Drugs 0.000 description 2
• 150000002170 ethers Chemical class 0.000 description 2
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
• LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 2
• 229940093471 ethyl oleate Drugs 0.000 description 2
• DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 2
• 230000002349 favourable effect Effects 0.000 description 2
• 230000035558 fertility Effects 0.000 description 2
• 235000013305 food Nutrition 0.000 description 2
• 239000012634 fragment Substances 0.000 description 2
• 229940045109 genistein Drugs 0.000 description 2
• 235000006539 genistein Nutrition 0.000 description 2
• ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 2
• 229940050410 gluconate Drugs 0.000 description 2
• 239000008187 granular material Substances 0.000 description 2
• 229940093915 gynecological organic acid Drugs 0.000 description 2
• 150000004820 halides Chemical class 0.000 description 2
• 210000002216 heart Anatomy 0.000 description 2
• 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
• 238000013537 high throughput screening Methods 0.000 description 2
• 102000056427 human CFTR Human genes 0.000 description 2
• QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 2
• 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 2
• 239000000815 hypotonic solution Substances 0.000 description 2
• 229960000905 indomethacin Drugs 0.000 description 2
• 208000015181 infectious disease Diseases 0.000 description 2
• 230000004054 inflammatory process Effects 0.000 description 2
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
• SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
• 238000002955 isolation Methods 0.000 description 2
• 229960003299 ketamine Drugs 0.000 description 2
• JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
• 238000011068 loading method Methods 0.000 description 2
• 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 description 2
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
• 210000000713 mesentery Anatomy 0.000 description 2
• 230000004060 metabolic process Effects 0.000 description 2
• FNEZBBILNYNQGC-UHFFFAOYSA-N methyl 2-(3,6-diamino-9h-xanthen-9-yl)benzoate Chemical compound COC(=O)C1=CC=CC=C1C1C2=CC=C(N)C=C2OC2=CC(N)=CC=C21 FNEZBBILNYNQGC-UHFFFAOYSA-N 0.000 description 2
• UQDUPQYQJKYHQI-UHFFFAOYSA-N methyl laurate Chemical compound CCCCCCCCCCCC(=O)OC UQDUPQYQJKYHQI-UHFFFAOYSA-N 0.000 description 2
• 230000004048 modification Effects 0.000 description 2
• 238000012986 modification Methods 0.000 description 2
• 235000019796 monopotassium phosphate Nutrition 0.000 description 2
• 230000000420 mucociliary effect Effects 0.000 description 2
• TXXHDPDFNKHHGW-UHFFFAOYSA-N muconic acid Chemical compound OC(=O)C=CC=CC(O)=O TXXHDPDFNKHHGW-UHFFFAOYSA-N 0.000 description 2
• 210000004877 mucosa Anatomy 0.000 description 2
• 210000003097 mucus Anatomy 0.000 description 2
• 210000003205 muscle Anatomy 0.000 description 2
• FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
• 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 description 2
• 239000002674 ointment Substances 0.000 description 2
• 238000003305 oral gavage Methods 0.000 description 2
• 150000007524 organic acids Chemical class 0.000 description 2
• 235000005985 organic acids Nutrition 0.000 description 2
• FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
• 230000010412 perfusion Effects 0.000 description 2
• 229940066842 petrolatum Drugs 0.000 description 2
• 235000011007 phosphoric acid Nutrition 0.000 description 2
• 230000026731 phosphorylation Effects 0.000 description 2
• 238000006366 phosphorylation reaction Methods 0.000 description 2
• 230000004962 physiological condition Effects 0.000 description 2
• 229940113116 polyethylene glycol 1000 Drugs 0.000 description 2
• GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 2
• 229920001592 potato starch Polymers 0.000 description 2
• 239000000843 powder Substances 0.000 description 2
• 238000001556 precipitation Methods 0.000 description 2
• 239000003755 preservative agent Substances 0.000 description 2
• 230000008569 process Effects 0.000 description 2
• 210000001187 pylorus Anatomy 0.000 description 2
• 125000002098 pyridazinyl group Chemical group 0.000 description 2
• ARIWANIATODDMH-UHFFFAOYSA-N rac-1-monolauroylglycerol Chemical compound CCCCCCCCCCCC(=O)OCC(O)CO ARIWANIATODDMH-UHFFFAOYSA-N 0.000 description 2
• 150000003254 radicals Chemical class 0.000 description 2
• 238000010992 reflux Methods 0.000 description 2
• 229960004889 salicylic acid Drugs 0.000 description 2
• 230000003248 secreting effect Effects 0.000 description 2
• BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 description 2
• HKZLPVFGJNLROG-UHFFFAOYSA-M silver monochloride Chemical compound [Cl-].[Ag+] HKZLPVFGJNLROG-UHFFFAOYSA-M 0.000 description 2
• 239000002356 single layer Substances 0.000 description 2
• 239000002002 slurry Substances 0.000 description 2
• 150000003384 small molecules Chemical class 0.000 description 2
• 239000011734 sodium Substances 0.000 description 2
• 241000894007 species Species 0.000 description 2
• 239000003381 stabilizer Substances 0.000 description 2
• 239000007858 starting material Substances 0.000 description 2
• 210000002784 stomach Anatomy 0.000 description 2
• 238000007920 subcutaneous administration Methods 0.000 description 2
• 210000004878 submucosal gland Anatomy 0.000 description 2
• KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
• 239000000725 suspension Substances 0.000 description 2
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
• 239000012049 topical pharmaceutical composition Substances 0.000 description 2
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
• 230000037317 transdermal delivery Effects 0.000 description 2
• 125000004385 trihaloalkyl group Chemical group 0.000 description 2
• 125000004953 trihalomethyl group Chemical group 0.000 description 2
• 229960004418 trolamine Drugs 0.000 description 2
• NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
• 229960001722 verapamil Drugs 0.000 description 2
• 229940118696 vibrio cholerae Drugs 0.000 description 2
• BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 2
• 229960001600 xylazine Drugs 0.000 description 2
• QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
• ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
• WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
• MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
• BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
• WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
• QMMJWQMCMRUYTG-UHFFFAOYSA-N 1,2,4,5-tetrachloro-3-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=C(Cl)C(Cl)=CC(Cl)=C1Cl QMMJWQMCMRUYTG-UHFFFAOYSA-N 0.000 description 1
• NOLHRFLIXVQPSZ-UHFFFAOYSA-N 1,3-thiazolidin-4-one Chemical compound O=C1CSCN1 NOLHRFLIXVQPSZ-UHFFFAOYSA-N 0.000 description 1
• HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 1
• JFLSOKIMYBSASW-UHFFFAOYSA-N 1-chloro-2-[chloro(diphenyl)methyl]benzene Chemical compound ClC1=CC=CC=C1C(Cl)(C=1C=CC=CC=1)C1=CC=CC=C1 JFLSOKIMYBSASW-UHFFFAOYSA-N 0.000 description 1
• AMMPLVWPWSYRDR-UHFFFAOYSA-N 1-methylbicyclo[2.2.2]oct-2-ene-4-carboxylic acid Chemical compound C1CC2(C(O)=O)CCC1(C)C=C2 AMMPLVWPWSYRDR-UHFFFAOYSA-N 0.000 description 1
• NZJXADCEESMBPW-UHFFFAOYSA-N 1-methylsulfinyldecane Chemical compound CCCCCCCCCCS(C)=O NZJXADCEESMBPW-UHFFFAOYSA-N 0.000 description 1
• IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
• KLIDCXVFHGNTTM-UHFFFAOYSA-N 2,6-dimethoxyphenol Chemical group COC1=CC=CC(OC)=C1O KLIDCXVFHGNTTM-UHFFFAOYSA-N 0.000 description 1
• 125000006276 2-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C(*)C([H])=C1[H] 0.000 description 1
• 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 1
• 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 description 1
• LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
• 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 description 1
• NMPJFFWYEIIGFW-UHFFFAOYSA-N 3-(3-chlorophenyl)-6-(trifluoromethyl)-1h-benzimidazol-2-one Chemical compound O=C1NC2=CC(C(F)(F)F)=CC=C2N1C1=CC=CC(Cl)=C1 NMPJFFWYEIIGFW-UHFFFAOYSA-N 0.000 description 1
• XLZYKTYMLBOINK-UHFFFAOYSA-N 3-(4-hydroxybenzoyl)benzoic acid Chemical compound OC(=O)C1=CC=CC(C(=O)C=2C=CC(O)=CC=2)=C1 XLZYKTYMLBOINK-UHFFFAOYSA-N 0.000 description 1
• VIUDTWATMPPKEL-UHFFFAOYSA-N 3-(trifluoromethyl)aniline Chemical compound NC1=CC=CC(C(F)(F)F)=C1 VIUDTWATMPPKEL-UHFFFAOYSA-N 0.000 description 1
• BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
• 125000006275 3-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C([H])C(*)=C1[H] 0.000 description 1
• 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 1
• ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
• 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 description 1
• 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 description 1
• HBTAOSGHCXUEKI-UHFFFAOYSA-N 4-chloro-n,n-dimethyl-3-nitrobenzenesulfonamide Chemical compound CN(C)S(=O)(=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 HBTAOSGHCXUEKI-UHFFFAOYSA-N 0.000 description 1
• RJWBTWIBUIGANW-UHFFFAOYSA-N 4-chlorobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=C(Cl)C=C1 RJWBTWIBUIGANW-UHFFFAOYSA-N 0.000 description 1
• 125000004801 4-cyanophenyl group Chemical group [H]C1=C([H])C(C#N)=C([H])C([H])=C1* 0.000 description 1
• 125000004860 4-ethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])C([H])([H])[H] 0.000 description 1
• 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
• 125000004199 4-trifluoromethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C(F)(F)F 0.000 description 1
• QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
• 102100024645 ATP-binding cassette sub-family C member 8 Human genes 0.000 description 1
• 206010000060 Abdominal distension Diseases 0.000 description 1
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
• 239000004382 Amylase Substances 0.000 description 1
• 102000013142 Amylases Human genes 0.000 description 1
• 108010065511 Amylases Proteins 0.000 description 1
• 102000004888 Aquaporin 1 Human genes 0.000 description 1
• 108090001004 Aquaporin 1 Proteins 0.000 description 1
• 102000010637 Aquaporins Human genes 0.000 description 1
• 241000894006 Bacteria Species 0.000 description 1
• 208000035143 Bacterial infection Diseases 0.000 description 1
• 239000005711 Benzoic acid Substances 0.000 description 1
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
• UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
• 241000589876 Campylobacter Species 0.000 description 1
• 239000004215 Carbon black (E152) Substances 0.000 description 1
• 102000014914 Carrier Proteins Human genes 0.000 description 1
• 241000282693 Cercopithecidae Species 0.000 description 1
• LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
• 102000011045 Chloride Channels Human genes 0.000 description 1
• 108010062745 Chloride Channels Proteins 0.000 description 1
• 208000000668 Chronic Pancreatitis Diseases 0.000 description 1
• WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
• 208000026372 Congenital cystic kidney disease Diseases 0.000 description 1
• 241000699800 Cricetinae Species 0.000 description 1
• 208000011231 Crohn disease Diseases 0.000 description 1
• 208000008953 Cryptosporidiosis Diseases 0.000 description 1
• 206010011502 Cryptosporidiosis infection Diseases 0.000 description 1
• 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 1
• 108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 description 1
• 241000179197 Cyclospora Species 0.000 description 1
• 208000026292 Cystic Kidney disease Diseases 0.000 description 1
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
• RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
• RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Chemical group OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
• FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
• 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
• LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical class COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
• SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
• 241000224432 Entamoeba histolytica Species 0.000 description 1
• 108010001687 Enterotoxin Receptors Proteins 0.000 description 1
• 102000004190 Enzymes Human genes 0.000 description 1
• 108090000790 Enzymes Proteins 0.000 description 1
• 206010016952 Food poisoning Diseases 0.000 description 1
• 208000019331 Foodborne disease Diseases 0.000 description 1
• BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
• 206010017533 Fungal infection Diseases 0.000 description 1
• 208000018522 Gastrointestinal disease Diseases 0.000 description 1
• 108010010803 Gelatin Proteins 0.000 description 1
• 241000699694 Gerbillinae Species 0.000 description 1
• 241000224466 Giardia Species 0.000 description 1
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Chemical group OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
• 241000282575 Gorilla Species 0.000 description 1
• 101000760570 Homo sapiens ATP-binding cassette sub-family C member 8 Proteins 0.000 description 1
• 208000032754 Infant Death Diseases 0.000 description 1
• 206010061218 Inflammation Diseases 0.000 description 1
• 102000004877 Insulin Human genes 0.000 description 1
• 108090001061 Insulin Proteins 0.000 description 1
• 102000037862 Ion Transporter Human genes 0.000 description 1
• 108091006671 Ion Transporter Proteins 0.000 description 1
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical group OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
• 229930182816 L-glutamine Natural products 0.000 description 1
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
• 239000005639 Lauric acid Substances 0.000 description 1
• 240000007472 Leucaena leucocephala Species 0.000 description 1
• 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
• 229930195725 Mannitol Natural products 0.000 description 1
• RJUFJBKOKNCXHH-UHFFFAOYSA-N Methyl propionate Chemical compound CCC(=O)OC RJUFJBKOKNCXHH-UHFFFAOYSA-N 0.000 description 1
• TXXHDPDFNKHHGW-CCAGOZQPSA-N Muconic acid Natural products OC(=O)\C=C/C=C\C(O)=O TXXHDPDFNKHHGW-CCAGOZQPSA-N 0.000 description 1
• 241001529936 Murinae Species 0.000 description 1
• 241000282339 Mustela Species 0.000 description 1
• 208000031888 Mycoses Diseases 0.000 description 1
• GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
• 239000005642 Oleic acid Substances 0.000 description 1
• ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
• MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical class OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
• 241000282577 Pan troglodytes Species 0.000 description 1
• 208000016222 Pancreatic disease Diseases 0.000 description 1
• 206010033649 Pancreatitis chronic Diseases 0.000 description 1
• QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
• 208000037581 Persistent Infection Diseases 0.000 description 1
• 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
• 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
• RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
• 229920001213 Polysorbate 20 Polymers 0.000 description 1
• 108050007961 Potassium transporters Proteins 0.000 description 1
• 102000003923 Protein Kinase C Human genes 0.000 description 1
• 108090000315 Protein Kinase C Proteins 0.000 description 1
• IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
• 206010057190 Respiratory tract infections Diseases 0.000 description 1
• 229940124639 Selective inhibitor Drugs 0.000 description 1
• BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
• 241000607768 Shigella Species 0.000 description 1
• DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
• 229920002472 Starch Polymers 0.000 description 1
• 235000021355 Stearic acid Nutrition 0.000 description 1
• FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
• 206010051511 Viral diarrhoea Diseases 0.000 description 1
• 208000036142 Viral infection Diseases 0.000 description 1
• 241000700605 Viruses Species 0.000 description 1
• 239000003875 Wang resin Substances 0.000 description 1
• 239000001089 [(2R)-oxolan-2-yl]methanol Substances 0.000 description 1
• NERFNHBZJXXFGY-UHFFFAOYSA-N [4-[(4-methylphenyl)methoxy]phenyl]methanol Chemical compound C1=CC(C)=CC=C1COC1=CC=C(CO)C=C1 NERFNHBZJXXFGY-UHFFFAOYSA-N 0.000 description 1
• 238000002835 absorbance Methods 0.000 description 1
• 150000001241 acetals Chemical class 0.000 description 1
• DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
• 239000004480 active ingredient Substances 0.000 description 1
• 239000013543 active substance Substances 0.000 description 1
• 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
• 239000012790 adhesive layer Substances 0.000 description 1
• 239000000048 adrenergic agonist Substances 0.000 description 1
• 238000013308 adult mouse model Methods 0.000 description 1
• 230000002411 adverse Effects 0.000 description 1
• 210000005058 airway cell Anatomy 0.000 description 1
• 210000001552 airway epithelial cell Anatomy 0.000 description 1
• 150000001298 alcohols Chemical class 0.000 description 1
• 229910001413 alkali metal ion Inorganic materials 0.000 description 1
• 150000001346 alkyl aryl ethers Chemical class 0.000 description 1
• 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
• OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 description 1
• BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
• 229910052782 aluminium Inorganic materials 0.000 description 1
• 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
• 150000001408 amides Chemical class 0.000 description 1
• 235000001014 amino acid Nutrition 0.000 description 1
• 150000001413 amino acids Chemical class 0.000 description 1
• 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
• 230000003321 amplification Effects 0.000 description 1
• 235000019418 amylase Nutrition 0.000 description 1
• 238000000540 analysis of variance Methods 0.000 description 1
• 208000006673 asthma Diseases 0.000 description 1
• 239000012298 atmosphere Substances 0.000 description 1
• 208000022362 bacterial infectious disease Diseases 0.000 description 1
• OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
• 229960000686 benzalkonium chloride Drugs 0.000 description 1
• SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
• 229940092714 benzenesulfonic acid Drugs 0.000 description 1
• 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
• 235000010233 benzoic acid Nutrition 0.000 description 1
• 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
• 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
• 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
• CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
• GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 description 1
• 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
• 230000027455 binding Effects 0.000 description 1
• 239000004305 biphenyl Substances 0.000 description 1
• 235000010290 biphenyl Nutrition 0.000 description 1
• 230000000903 blocking effect Effects 0.000 description 1
• 125000005620 boronic acid group Chemical class 0.000 description 1
• 229910052794 bromium Inorganic materials 0.000 description 1
• CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 description 1
• KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
• 210000004899 c-terminal region Anatomy 0.000 description 1
• 230000003491 cAMP production Effects 0.000 description 1
• 239000011575 calcium Substances 0.000 description 1
• 229910052791 calcium Inorganic materials 0.000 description 1
• 239000001110 calcium chloride Substances 0.000 description 1
• 235000011148 calcium chloride Nutrition 0.000 description 1
• 229910001628 calcium chloride Inorganic materials 0.000 description 1
• 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
• 239000004202 carbamide Substances 0.000 description 1
• 125000002837 carbocyclic group Chemical group 0.000 description 1
• 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
• 239000001768 carboxy methyl cellulose Substances 0.000 description 1
• 150000001735 carboxylic acids Chemical class 0.000 description 1
• 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
• 239000000969 carrier Substances 0.000 description 1
• 230000003197 catalytic effect Effects 0.000 description 1
• 238000004113 cell culture Methods 0.000 description 1
• 210000000170 cell membrane Anatomy 0.000 description 1
• 230000001413 cellular effect Effects 0.000 description 1
• 230000007541 cellular toxicity Effects 0.000 description 1
• 150000001805 chlorine compounds Chemical class 0.000 description 1
• FOCAUTSVDIKZOP-UHFFFAOYSA-N chloroacetic acid Chemical compound OC(=O)CCl FOCAUTSVDIKZOP-UHFFFAOYSA-N 0.000 description 1
• 229940106681 chloroacetic acid Drugs 0.000 description 1
• 230000001684 chronic effect Effects 0.000 description 1
• 208000037976 chronic inflammation Diseases 0.000 description 1
• 235000013985 cinnamic acid Nutrition 0.000 description 1
• 229930016911 cinnamic acid Natural products 0.000 description 1
• NNBZCPXTIHJBJL-AOOOYVTPSA-N cis-decalin Chemical compound C1CCC[C@H]2CCCC[C@H]21 NNBZCPXTIHJBJL-AOOOYVTPSA-N 0.000 description 1
• 230000010405 clearance mechanism Effects 0.000 description 1
• 229940110456 cocoa butter Drugs 0.000 description 1
• 235000019868 cocoa butter Nutrition 0.000 description 1
• 238000012937 correction Methods 0.000 description 1
• 239000006071 cream Substances 0.000 description 1
• 229940109239 creatinine Drugs 0.000 description 1
• 125000004802 cyanophenyl group Chemical group 0.000 description 1
• 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• 229940097362 cyclodextrins Drugs 0.000 description 1
• 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
• 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
• 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
• 230000006378 damage Effects 0.000 description 1
• 230000034994 death Effects 0.000 description 1
• 231100000517 death Toxicity 0.000 description 1
• 238000001212 derivatisation Methods 0.000 description 1
• 238000001514 detection method Methods 0.000 description 1
• 230000000741 diarrhetic effect Effects 0.000 description 1
• PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
• 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
• MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 1
• 229940075557 diethylene glycol monoethyl ether Drugs 0.000 description 1
• 229940031578 diisopropyl adipate Drugs 0.000 description 1
• 150000005218 dimethyl ethers Chemical class 0.000 description 1
• 230000003292 diminished effect Effects 0.000 description 1
• 239000012153 distilled water Substances 0.000 description 1
• LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 1
• 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical group CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
• 229960004679 doxorubicin Drugs 0.000 description 1
• 238000012377 drug delivery Methods 0.000 description 1
• 210000001198 duodenum Anatomy 0.000 description 1
• 239000003792 electrolyte Substances 0.000 description 1
• 230000007831 electrophysiology Effects 0.000 description 1
• 238000002001 electrophysiology Methods 0.000 description 1
• 229940007078 entamoeba histolytica Drugs 0.000 description 1
• 239000002702 enteric coating Substances 0.000 description 1
• 238000009505 enteric coating Methods 0.000 description 1
• 230000010235 enterohepatic circulation Effects 0.000 description 1
• AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
• CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
• XYIBRDXRRQCHLP-UHFFFAOYSA-N ethyl acetoacetate Chemical compound CCOC(=O)CC(C)=O XYIBRDXRRQCHLP-UHFFFAOYSA-N 0.000 description 1
• 230000005284 excitation Effects 0.000 description 1
• 230000029142 excretion Effects 0.000 description 1
• 238000001125 extrusion Methods 0.000 description 1
• 239000002871 fertility agent Substances 0.000 description 1
• 239000000796 flavoring agent Substances 0.000 description 1
• 238000001506 fluorescence spectroscopy Methods 0.000 description 1
• 229910052731 fluorine Inorganic materials 0.000 description 1
• 235000013355 food flavoring agent Nutrition 0.000 description 1
• 239000001530 fumaric acid Substances 0.000 description 1
• 235000011087 fumaric acid Nutrition 0.000 description 1
• 125000002541 furyl group Chemical group 0.000 description 1
• 210000000232 gallbladder Anatomy 0.000 description 1
• 210000001035 gastrointestinal tract Anatomy 0.000 description 1
• 238000003304 gavage Methods 0.000 description 1
• 239000000499 gel Substances 0.000 description 1
• 229920000159 gelatin Polymers 0.000 description 1
• 235000019322 gelatine Nutrition 0.000 description 1
• 235000011852 gelatine desserts Nutrition 0.000 description 1
• 239000012362 glacial acetic acid Substances 0.000 description 1
• 210000004907 gland Anatomy 0.000 description 1
• 230000024924 glomerular filtration Effects 0.000 description 1
• 239000000174 gluconic acid Chemical group 0.000 description 1
• 235000012208 gluconic acid Nutrition 0.000 description 1
• 239000004220 glutamic acid Chemical group 0.000 description 1
• 235000013922 glutamic acid Nutrition 0.000 description 1
• 125000005456 glyceride group Chemical group 0.000 description 1
• 229940068939 glyceryl monolaurate Drugs 0.000 description 1
• 230000012010 growth Effects 0.000 description 1
• 239000001963 growth medium Substances 0.000 description 1
• 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 description 1
• BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 1
• 229960003132 halothane Drugs 0.000 description 1
• 238000005534 hematocrit Methods 0.000 description 1
• 150000002373 hemiacetals Chemical class 0.000 description 1
• 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 238000004128 high performance liquid chromatography Methods 0.000 description 1
• 229940088597 hormone Drugs 0.000 description 1
• 239000005556 hormone Substances 0.000 description 1
• 150000004677 hydrates Chemical class 0.000 description 1
• 229930195733 hydrocarbon Natural products 0.000 description 1
• 239000000017 hydrogel Substances 0.000 description 1
• 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
• 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
• 125000004464 hydroxyphenyl group Chemical group 0.000 description 1
• 230000002102 hyperpolarization Effects 0.000 description 1
• 230000002218 hypoglycaemic effect Effects 0.000 description 1
• 125000002883 imidazolyl group Chemical group 0.000 description 1
• 238000011534 incubation Methods 0.000 description 1
• 125000001041 indolyl group Chemical group 0.000 description 1
• 230000001939 inductive effect Effects 0.000 description 1
• 208000000509 infertility Diseases 0.000 description 1
• 230000036512 infertility Effects 0.000 description 1
• 231100000535 infertility Toxicity 0.000 description 1
• 201000009863 inflammatory diarrhea Diseases 0.000 description 1
• 230000002757 inflammatory effect Effects 0.000 description 1
• 230000000977 initiatory effect Effects 0.000 description 1
• 229940125396 insulin Drugs 0.000 description 1
• 230000003914 insulin secretion Effects 0.000 description 1
• 230000003993 interaction Effects 0.000 description 1
• 238000011835 investigation Methods 0.000 description 1
• 229910052740 iodine Inorganic materials 0.000 description 1
• 125000002346 iodo group Chemical group I* 0.000 description 1
• QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
• 229940074928 isopropyl myristate Drugs 0.000 description 1
• XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
• 229940075495 isopropyl palmitate Drugs 0.000 description 1
• 239000007951 isotonicity adjuster Substances 0.000 description 1
• 125000000842 isoxazolyl group Chemical group 0.000 description 1
• 239000004310 lactic acid Substances 0.000 description 1
• 235000014655 lactic acid Nutrition 0.000 description 1
• 239000008101 lactose Substances 0.000 description 1
• 239000000787 lecithin Substances 0.000 description 1
• 229940067606 lecithin Drugs 0.000 description 1
• 235000010445 lecithin Nutrition 0.000 description 1
• 231100000518 lethal Toxicity 0.000 description 1
• 230000001665 lethal effect Effects 0.000 description 1
• 230000003908 liver function Effects 0.000 description 1
• 244000144972 livestock Species 0.000 description 1
• 230000033001 locomotion Effects 0.000 description 1
• 239000006210 lotion Substances 0.000 description 1
• 239000000314 lubricant Substances 0.000 description 1
• 229920002521 macromolecule Polymers 0.000 description 1
• 235000019359 magnesium stearate Nutrition 0.000 description 1
• VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
• 239000011976 maleic acid Substances 0.000 description 1
• 239000001630 malic acid Substances 0.000 description 1
• 235000011090 malic acid Nutrition 0.000 description 1
• 229960002510 mandelic acid Drugs 0.000 description 1
• 239000000594 mannitol Substances 0.000 description 1
• 235000010355 mannitol Nutrition 0.000 description 1
• 239000002609 medium Substances 0.000 description 1
• 238000002844 melting Methods 0.000 description 1
• 230000008018 melting Effects 0.000 description 1
• 229910021645 metal ion Inorganic materials 0.000 description 1
• 229940098779 methanesulfonic acid Drugs 0.000 description 1
• WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
• 229940017219 methyl propionate Drugs 0.000 description 1
• 230000000813 microbial effect Effects 0.000 description 1
• 230000003278 mimic effect Effects 0.000 description 1
• 239000002480 mineral oil Substances 0.000 description 1
• 235000010446 mineral oil Nutrition 0.000 description 1
• 150000007522 mineralic acids Chemical class 0.000 description 1
• 244000309715 mini pig Species 0.000 description 1
• 238000002156 mixing Methods 0.000 description 1
• 125000002950 monocyclic group Chemical group 0.000 description 1
• 210000004165 myocardium Anatomy 0.000 description 1
• 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
• 125000001624 naphthyl group Chemical group 0.000 description 1
• 210000002569 neuron Anatomy 0.000 description 1
• 229910017604 nitric acid Inorganic materials 0.000 description 1
• 125000004971 nitroalkyl group Chemical group 0.000 description 1
• 150000002829 nitrogen Chemical class 0.000 description 1
• 125000004433 nitrogen atom Chemical group N* 0.000 description 1
• QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
• 125000006501 nitrophenyl group Chemical group 0.000 description 1
• JFNLZVQOOSMTJK-KNVOCYPGSA-N norbornene Chemical compound C1[C@@H]2CC[C@H]1C=C2 JFNLZVQOOSMTJK-KNVOCYPGSA-N 0.000 description 1
• 238000003199 nucleic acid amplification method Methods 0.000 description 1
• QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
• OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
• 239000003921 oil Substances 0.000 description 1
• ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
• 229940055577 oleyl alcohol Drugs 0.000 description 1
• XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
• 150000007530 organic bases Chemical class 0.000 description 1
• 150000002905 orthoesters Chemical class 0.000 description 1
• 230000003204 osmotic effect Effects 0.000 description 1
• 125000001715 oxadiazolyl group Chemical group 0.000 description 1
• 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
• 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 1
• 239000003002 pH adjusting agent Substances 0.000 description 1
• 244000045947 parasite Species 0.000 description 1
• 238000007911 parenteral administration Methods 0.000 description 1
• 239000006072 paste Substances 0.000 description 1
• 244000052769 pathogen Species 0.000 description 1
• 230000001575 pathological effect Effects 0.000 description 1
• 230000007170 pathology Effects 0.000 description 1
• 230000000149 penetrating effect Effects 0.000 description 1
• 229960001412 pentobarbital Drugs 0.000 description 1
• 229960002275 pentobarbital sodium Drugs 0.000 description 1
• 231100000435 percutaneous penetration Toxicity 0.000 description 1
• 125000005010 perfluoroalkyl group Chemical group 0.000 description 1
• 230000003285 pharmacodynamic effect Effects 0.000 description 1
• WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
• 125000003884 phenylalkyl group Chemical group 0.000 description 1
• UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
• 125000001639 phenylmethylene group Chemical group [H]C(=*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
• 150000003016 phosphoric acids Chemical class 0.000 description 1
• PHUTUTUABXHXLW-UHFFFAOYSA-N pindolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=NC=C[C]12 PHUTUTUABXHXLW-UHFFFAOYSA-N 0.000 description 1
• 229960002508 pindolol Drugs 0.000 description 1
• IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
• 229920003023 plastic Polymers 0.000 description 1
• 239000004033 plastic Substances 0.000 description 1
• 229960000502 poloxamer Drugs 0.000 description 1
• 229920001983 poloxamer Polymers 0.000 description 1
• 125000005575 polycyclic aromatic hydrocarbon group Chemical group 0.000 description 1
• 239000002952 polymeric resin Substances 0.000 description 1
• 229920005862 polyol Polymers 0.000 description 1
• 150000003077 polyols Chemical class 0.000 description 1
• WSHYKIAQCMIPTB-UHFFFAOYSA-M potassium;2-oxo-3-(3-oxo-1-phenylbutyl)chromen-4-olate Chemical compound [K+].[O-]C=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 WSHYKIAQCMIPTB-UHFFFAOYSA-M 0.000 description 1
• 230000003334 potential effect Effects 0.000 description 1
• 238000012545 processing Methods 0.000 description 1
• BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
• 239000001294 propane Substances 0.000 description 1
• 239000003380 propellant Substances 0.000 description 1
• 235000019260 propionic acid Nutrition 0.000 description 1
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 235000018102 proteins Nutrition 0.000 description 1
• 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
• 125000003373 pyrazinyl group Chemical group 0.000 description 1
• UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
• 125000004076 pyridyl group Chemical group 0.000 description 1
• 125000000714 pyrimidinyl group Chemical group 0.000 description 1
• HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
• 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
• 125000000168 pyrrolyl group Chemical group 0.000 description 1
• 229940107700 pyruvic acid Drugs 0.000 description 1
• IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
• 238000011555 rabbit model Methods 0.000 description 1
• 238000011552 rat model Methods 0.000 description 1
• 108020003175 receptors Proteins 0.000 description 1
• 102000005962 receptors Human genes 0.000 description 1
• 238000001953 recrystallisation Methods 0.000 description 1
• 210000005084 renal tissue Anatomy 0.000 description 1
• 230000002441 reversible effect Effects 0.000 description 1
• 238000012552 review Methods 0.000 description 1
• KIWUVOGUEXMXSV-UHFFFAOYSA-N rhodanine Chemical class O=C1CSC(=S)N1 KIWUVOGUEXMXSV-UHFFFAOYSA-N 0.000 description 1
• 238000011808 rodent model Methods 0.000 description 1
• 150000003902 salicylic acid esters Chemical class 0.000 description 1
• 239000012266 salt solution Substances 0.000 description 1
• 229930195734 saturated hydrocarbon Natural products 0.000 description 1
• HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
• 229910052711 selenium Inorganic materials 0.000 description 1
• 239000011669 selenium Substances 0.000 description 1
• 125000003748 selenium group Chemical group *[Se]* 0.000 description 1
• 238000000926 separation method Methods 0.000 description 1
• 238000012163 sequencing technique Methods 0.000 description 1
• 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
• 230000019491 signal transduction Effects 0.000 description 1
• 229960003310 sildenafil Drugs 0.000 description 1
• 239000000377 silicon dioxide Substances 0.000 description 1
• 231100000245 skin permeability Toxicity 0.000 description 1
• 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
• 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
• FDRCDNZGSXJAFP-UHFFFAOYSA-M sodium chloroacetate Chemical compound [Na+].[O-]C(=O)CCl FDRCDNZGSXJAFP-UHFFFAOYSA-M 0.000 description 1
• BTURAGWYSMTVOW-UHFFFAOYSA-M sodium dodecanoate Chemical compound [Na+].CCCCCCCCCCCC([O-])=O BTURAGWYSMTVOW-UHFFFAOYSA-M 0.000 description 1
• 229940082004 sodium laurate Drugs 0.000 description 1
• 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
• 238000001228 spectrum Methods 0.000 description 1
• 238000013222 sprague-dawley male rat Methods 0.000 description 1
• 238000010561 standard procedure Methods 0.000 description 1
• 239000008107 starch Substances 0.000 description 1
• 235000019698 starch Nutrition 0.000 description 1
• 239000008117 stearic acid Substances 0.000 description 1
• 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 239000008223 sterile water Substances 0.000 description 1
• 239000011550 stock solution Substances 0.000 description 1
• 210000000434 stratum corneum Anatomy 0.000 description 1
• 125000005017 substituted alkenyl group Chemical group 0.000 description 1
• 125000005346 substituted cycloalkyl group Chemical group 0.000 description 1
• 239000001384 succinic acid Substances 0.000 description 1
• 150000003455 sulfinic acids Chemical class 0.000 description 1
• 125000004964 sulfoalkyl group Chemical group 0.000 description 1
• 150000003460 sulfonic acids Chemical class 0.000 description 1
• 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
• 239000006228 supernatant Substances 0.000 description 1
• 230000008093 supporting effect Effects 0.000 description 1
• 239000004094 surface-active agent Substances 0.000 description 1
• 239000000375 suspending agent Substances 0.000 description 1
• 238000013268 sustained release Methods 0.000 description 1
• 239000012730 sustained-release form Substances 0.000 description 1
• 229920003002 synthetic resin Polymers 0.000 description 1
• 235000020357 syrup Nutrition 0.000 description 1
• 239000006188 syrup Substances 0.000 description 1
• 238000007910 systemic administration Methods 0.000 description 1
• 230000001839 systemic circulation Effects 0.000 description 1
• 230000009885 systemic effect Effects 0.000 description 1
• 239000000454 talc Substances 0.000 description 1
• 229910052623 talc Inorganic materials 0.000 description 1
• 239000011975 tartaric acid Substances 0.000 description 1
• 235000002906 tartaric acid Nutrition 0.000 description 1
• BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 1
• 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
• 125000003831 tetrazolyl group Chemical group 0.000 description 1
• 125000004525 thiadiazinyl group Chemical group S1NN=C(C=C1)* 0.000 description 1
• 125000001113 thiadiazolyl group Chemical group 0.000 description 1
• 125000005307 thiatriazolyl group Chemical group S1N=NN=C1* 0.000 description 1
• 150000003548 thiazolidines Chemical class 0.000 description 1
• 239000002562 thickening agent Substances 0.000 description 1
• 125000001544 thienyl group Chemical group 0.000 description 1
• 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 description 1
• 210000001685 thyroid gland Anatomy 0.000 description 1
• 238000013334 tissue model Methods 0.000 description 1
• 238000004448 titration Methods 0.000 description 1
• JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
• 238000011200 topical administration Methods 0.000 description 1
• 230000000699 topical effect Effects 0.000 description 1
• 231100000331 toxic Toxicity 0.000 description 1
• 230000002588 toxic effect Effects 0.000 description 1
• 230000024033 toxin binding Effects 0.000 description 1
• 210000003437 trachea Anatomy 0.000 description 1
• NNBZCPXTIHJBJL-UHFFFAOYSA-N trans-decahydronaphthalene Natural products C1CCCC2CCCCC21 NNBZCPXTIHJBJL-UHFFFAOYSA-N 0.000 description 1
• NNBZCPXTIHJBJL-MGCOHNPYSA-N trans-decalin Chemical compound C1CCC[C@@H]2CCCC[C@H]21 NNBZCPXTIHJBJL-MGCOHNPYSA-N 0.000 description 1
• 238000005809 transesterification reaction Methods 0.000 description 1
• 238000002054 transplantation Methods 0.000 description 1
• 125000004665 trialkylsilyl group Chemical group 0.000 description 1
• 125000004306 triazinyl group Chemical group 0.000 description 1
• 150000003852 triazoles Chemical class 0.000 description 1
• 125000001425 triazolyl group Chemical group 0.000 description 1
• 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 1
• 125000004950 trifluoroalkyl group Chemical group 0.000 description 1
• 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
• 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
• 229960000281 trometamol Drugs 0.000 description 1
• 238000002604 ultrasonography Methods 0.000 description 1
• 102000006030 urea transporter Human genes 0.000 description 1
• 108020003234 urea transporter Proteins 0.000 description 1
• 229940005605 valeric acid Drugs 0.000 description 1
• 210000001177 vas deferen Anatomy 0.000 description 1
• 235000013311 vegetables Nutrition 0.000 description 1
• 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
• 230000003612 virological effect Effects 0.000 description 1
• 230000000007 visual effect Effects 0.000 description 1
• 238000005303 weighing Methods 0.000 description 1
• 239000000080 wetting agent Substances 0.000 description 1